John received a BSc degree in chemistry from James Madison University (Harrisonburg, Virginia), followed by a MSc degree in biotechnology from Johns Hopkins University (Baltimore, Maryland). He then joined Dr. Phillip Dennis’s laboratory at the National Cancer Institute in Bethesda, Maryland, where they discovered signaling pathways that promote resistance to chemotherapy, elucidated mechanisms implicated in the initial stages of lung tumorigenesis, and developed small molecule inhibitors targeting constitutively active Akt in lung cancer. John obtained his PhD from University of California, San Diego in Dr. Alexandra Newton’s laboratory, where he discovered a novel class of phosphatases (PHLPP1 and PHLPP2) that act directly on Akt and PKC to decrease signalling through these pathways. Lastly, John trained as a postdoctoral fellow in Dr. Tony Hunter’s laboratory at the Salk Institute. Utilizing bioinformatic tools they screened cancer genomes to identify novel kinases implicated in cancer by the presence of functional somatic mutations. He joined the CRUK Manchester Institute as a group leader in September of 2010.
Eleanor Wendy Trotter
Potential graduate student and postdoctoral applicants who are interested in our research should contact John Brognard directly (email@example.com).